CD103+ TIL correlate with improved early stage patient survival in non-small cell lung cancer (NSCLC) and intraepithelial TIL density. CD103+ TIL show enhanced effector function against autologous tumor. The gene discussed is ITGAE; the disease is non-small cell lung carcinoma.